Autolus Therapeutics
AUTL
95 hedge funds and large institutions have $261M invested in Autolus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.14% less ownership
Funds ownership: 63.3% → 63.16% (-0.14%)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
14% less funds holding
Funds holding: 110 → 95 (-15)
34% less capital invested
Capital invested by funds: $395M → $261M (-$134M)
40% less call options, than puts
Call options by funds: $87K | Put options by funds: $145K
65% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$7.37M |
| 2 |
AC
Armistice Capital
New York
|
+$3.65M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.54M |
| 4 |
Axa
Paris,
France
|
+$2.64M |
| 5 |
Renaissance Technologies
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
| 2 |
Bank of New York Mellon
New York
|
-$3.93M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$2.95M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.43M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$1.25M |
AUTL Hedge Fund Activity: Q1 2025 in Review
95 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2025, worth a combined $261M — down 34% from $395M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AUTL and 8 opened new positions — a net loss of 15 holders — while 33 trimmed existing stakes and 30 added.
The largest buyer was Deep Track Capital, adding an estimated $7.37M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.
- 95 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2025, down from 110 in Q4 2024.
- Funds reported $261M of Autolus Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 8 funds opened new Autolus Therapeutics positions in Q1 2025 and 23 closed out, a net change of -15 holders.
- The largest Autolus Therapeutics buyer in Q1 2025 was Deep Track Capital, an estimated $7.37M added.
- The largest Autolus Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2025.